Risques des médicaments anti-inflammatoires et immunosuppresseurs au cours de la grossesse
Author:
- 1 June 2011
- journal article
- review article
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 32, S31-S35
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics RegisterAnnals of the Rheumatic Diseases, 2011
- Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's DiseaseJournal of Crohn's and Colitis, 2010
- Anti-TNF Antibody Therapy for Inflammatory Bowel Disease During Pregnancy: A Clinical ReviewCurrent Drug Targets, 2010
- Effects of Intrauterine Exposure to Synthetic Glucocorticoids on Fetal, Newborn, and Infant Hypothalamic-Pituitary-Adrenal Axis Function in Humans: A Systematic ReviewEndocrine Reviews, 2009
- Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugsRheumatology, 2008
- Anti-inflammatory and immunosuppressive drugs and reproductionArthritis Research & Therapy, 2006
- Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort studyBMJ, 2003
- Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studiesTeratology, 2000
- Placental 11β‐hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposureClinical Endocrinology, 1997
- Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin treatmentAmerican Journal of Obstetrics and Gynecology, 1992